Multiple Myeloma

Long-term outcomes from MAIA support the use of daratumumab plus lenalidomide and dexamethasone for ≥18 months in newly diagnosed, transplant ineligible MM patients.

A discrete-choice experiment and best-worst scaling survey identified the most and least important multiple myeloma treatment characteristics to patients and their caregivers.

Cohort B of CARTITUDE-2 evaluated the safety and efficacy of cilta-cel in high-risk patients who experienced early clinical relapse to determine its use in earlier lines of therapy.

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM.

Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.

The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.

Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM.